Cancer Clinical Trials
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Learn MoreWhat is the purpose of this study?
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
Eligibility
- Age ≥ 18 years on the day of signing the consent form, except for adolescents with Ewing Sarcoma or other malignancies for which there is a biological rationale to support participation, in which case the participant is ≥ 16 years old.
- Has a metastatic or locally advanced and unresectable solid tumor.
- Has at least 1 measurable lesion or evaluable disease per RECIST v1.1.
- Has an ECOG performance status ≤ 2 at screening.
- Has adequate organ function as defined in the protocol.
- Has received prior radiotherapy within 2 weeks of treatment.
- Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate, provided they are radiologically stable
- Has received treatment with any local or systemic anticancer therapy or investigational anticancer agent within 14 days or 5 half-lives, whichever is shorter.
- Had major surgery within 28 days before study therapy administration
- Has toxicities from previous anticancer therapies that have not resolved to baseline levels, with the exception of alopecia and peripheral neuropathy.
- Has previously received a RBM39 inhibitor/degrader.
Where can I participate?
More about this Clinical TrialWhat is the full name of this Clinical Trial?
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Disease Type/ConditionAdvanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
- Co-InvestigatorsMonica M. Mita, MD, Carlos R. Becerra, MD, Chelsea Brown, NP, Yaser Homsi, MD, Simon Khagi, MD, Adrienne Norquist, NP, Steven R. Grossman, MD, Tara E. Seery, MD, Cori Chastain, NP
- Age GroupChild, Adult, Older Adult
- PhaseI
- ClinicalTrials.gov IDNCT07197554
- Key Eligibilityclinicaltrials.gov
- How do I learn more about this study?Lauren Wagner
lauren.wagner@hoag.org
Stay up-to-date on the latest news from Hoag
By submitting this request, you agree to receive communications from Hoag and accept our Privacy Policy and Terms of Use.